Publications by authors named "Stebin Xavier"
Article Synopsis
- South Korea introduced a combined vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and type b invasive infections (DTaP-IPV/Hib) for infants starting at 2 months old in 2018, and a study evaluated its safety from 2018 to 2022.
- In total, 646 out of 660 infants were monitored for 30 days after vaccination, and 22.1% experienced adverse events (AEs), primarily mild issues like fever, injection site swelling, and irritability.
- The study found that most AEs were not serious, with very few leading to serious adverse events (SAEs), confirming that the DTaP-IPV/H
Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017-2021).
Hum Vaccin Immunother
December 2023
Human papillomavirus (HPV) infection is associated with the risk of developing certain cancers, including cancers of the cervix, vulva, vagina, penis, anus, rectum, and oropharynx. In 2016, the bivalent HPV-16/18 vaccine was included in the Korea National Immunization Program. This vaccine protects against HPV types 16 and 18 and other oncogenic HPV types predominant in cervical and anal cancers.
View Article and Find Full Text PDFArticle Synopsis
- Vaccine immunity against pertussis decreases over time, making adults and adolescents potential transmitters of the disease to infants, which is a concern since Russia doesn't have pertussis vaccines for older groups.
- A phase III study in Russia evaluated the safety and immune response of the dTpa vaccine in healthy participants aged 4 years and older, showing over 99% protection against diphtheria and tetanus, and over 96% positive for pertussis antibodies after one month.
- The dTpa booster vaccine induced a strong immune response in all ages tested, with minimal adverse effects reported, indicating it is a safe and effective option for enhancing immunity against diphtheria, tetanus, and pertussis.